🇺🇸 Lamivudine / Abacavir Sulfate in United States
21 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 21
Most-reported reactions
- Toxicity To Various Agents — 4 reports (19.05%)
- Foetal Exposure During Pregnancy — 3 reports (14.29%)
- Headache — 3 reports (14.29%)
- Arthralgia — 2 reports (9.52%)
- Cerebral Infarction — 2 reports (9.52%)
- Cholelithiasis — 2 reports (9.52%)
- Pneumocystis Jirovecii Pneumonia — 2 reports (9.52%)
- Abdominal Pain Upper — 1 report (4.76%)
- Accidental Overdose — 1 report (4.76%)
- Anaphylactic Shock — 1 report (4.76%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is Lamivudine / Abacavir Sulfate approved in United States?
Lamivudine / Abacavir Sulfate does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Lamivudine / Abacavir Sulfate in United States?
GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.